Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.36 |
| ▸ | PDE2A | O00408 | 4/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534740 | 0.81 | ALDH1A1 (0.39) | ALDH1A1HPGDF2GLAPDE3B | |
| SCHEMBL535369 | 0.81 | ALDH1A1 (0.39) | ALDH1A1HPGDF2GLAPDE3B | |
| SCHEMBL2872336 | 0.81 | PDE3B (0.42) | ALDH1A1HPGDF2GLAPARP1 | |
| SCHEMBL534712 | 0.79 | PARP1 (0.37) | ALDH1A1HPGDPARP1EGLN1HSD17B10 | |
| SCHEMBL534549 | 0.77 | ALDH1A1 (0.40) | ALDH1A1HPGDF2GLAPARP1 | |
| SCHEMBL2867975 | 0.76 | ALDH1A1 (0.37) | ALDH1A1HPGDF2GLAPARP1 | |
| SCHEMBL534453 | 0.76 | ALDH1A1 (0.51) | ALDH1A1HPGDKDM4EPTPN7CYP1A2 | |
| SCHEMBL17203163 | 0.75 | PARP1 (0.40) | ALDH1A1HPGDF2GLAPARP1 | |
| SCHEMBL2867979 | 0.75 | ALDH1A1 (0.38) | ALDH1A1HPGDF2GLAPARP1 | |
| SCHEMBL12817605 | 0.74 | ALDH1A1 (0.41) | ALDH1A1HPGDF2GLAPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507509-B2 | Saturated and insaturated bi- or tricyclic aryloxyacetamine derivatives and their use as fungicides | SYNGENTA CROP PROTECTION LLC (US) | 2013-08-13 | — | — | US | disclosed |
| US-8415272-B2 | Quinoline derivatives and their use as fungicides | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2231614-B1 | Quinoline derivatives and their use as fungicides | SYNGENTA PARTICIPATIONS AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| EP-2185518-B1 | Aryloxyacetamide derivatives and their use as fungicides | SYNGENTA PARTICIPATIONS AG (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20100298356-A1 | SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMINE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100280068-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| EP-2231614-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS FUNGICIDES | Syngenta Participations AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| EP-2185518-A2 | SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMIDE DERIVATIVES AND THEIR USE AS FUNGICIDES | Syngenta Participations AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009087098-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009030467-A2 | SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMIDE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG, (CH) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298356-A1 | SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMINE DERIVATIVES AND THEIR USE AS FUNGICIDES | CYP1A2, CYP1B1, CYP1A1 | ALDH1A1 109/4885HPGD 2661/4885F2 3671/4885 |
| US-20100280068-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS FUNGICIDES | CYP1A1, CYP3A7, CYP1A2 | ALDH1A1 350/4885HPGD 3732/4885F2 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.